hVIVO has signed a contract to conduct a pivotal phase 3 human challenge trial (HCT) for ILiAD Biotechnologies. This is a landmark moment for hVIVO, representing the first ever phase 3 HCT undertaken in Bordetella pertussis, the data from which, assuming a positive outcome, will be used to support the regulatory approval of a new therapy. We expect the initiation of this trial will raise the profile of HCTs and could lead to other developers using HCTs in similar pivotal trial design settings. I ....
